Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:08:00.644Z.
Calculation as of: 2026-10-06T17:08:00.644Z.
Quote observation: 2026-10-06T17:05:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$515.36M
PS Ratio
16624.39
TTM Avg
14908.47
3Y Avg
10316.98
5Y Avg
6997.34
Market Cap
$535.11M
PS Ratio
2.23
TTM Avg
5.40
3Y Avg
94.65
5Y Avg
94.65
Market Cap
$509.52M
PS Ratio
109.81
TTM Avg
130.95
3Y Avg
10788.70
5Y Avg
6253.86
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $523.83M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $524.71M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $515.36M | 16624.39 | 14908.47 | 10316.98 | 6997.34 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $535.11M | 2.23 | 5.40 | 94.65 | 94.65 |
| ProKidney Corp. (PROK)vs › | $536.32M | 655.65 | 390.36 | 569.23 | 569.23 |
| Delcath Systems, Inc. (DCTH)vs › | $536.12M | 5.62 | 5.23 | 17.66 | 17.71 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.52M | 109.81 | 130.95 | 10788.70 | 6253.86 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $537.90M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $509.60M | 8.38 | 4.86 | 4.00 | 6.89 |
| Crescent Biopharma, Inc. (CBIO)vs › | $503.30M | 42.35 | 40.07 | 1866.17 | 1168.37 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-27 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
